Urologie pro praxi 4/2001
Inhibitory 5alfa-reduktázy v praxi
5-alfa Reductase Inhibitors in the Practice The clinical picture of benign prostatic hyperplasia consists of three components: the worsening in urodynamic parameters of miction, prostate enlargement and unpleasant miction symptoms. By conservative treatment of benign prostatic hyperplasia (BPH) the alfa-blockers and 5-alpha reductase inhibitors are used, that means enzyme transforming the testosterone (T) into an effective dihydrotestosterone (DHT). The longterm clinical exploration dokuments that finasteride in the dose of 5mg/day is the only medicament of reach that involve positivly all three components to reduce the risk of acute urine retention in 57 per cent, the risk of operation of 55 per cent and diminishing of prostate of 20 per cent. The near future will show how effective the conservative treatment of BPH by new dual inhibitors of 5-alfa reductase realy is, while the development and effect confirmation is just going through. Key words: Benign prostatic hyperplasia (BPH), 5-alpha reductase inhibitors, finasteride.
